% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • nowwheretogo22004 nowwheretogo22004 Oct 18, 2012 3:09 PM Flag


    They lost their kidney failure drug today, so to me that means if they still want to spin out Abbvie, they will need to talk up the rest of their pipeline even more. That means more air time for Elagolix! If they want still want to do this before the 1st of the year, it also means this will all happen real soon.

    Normally, Abbott keeps real quit about anything they in their pipeline. With the company splitting, they don't have that luxury. What was suppose to be a very quiet time for Elagolix, will not be. Anyway, that's why I bought some more.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Really interesting that you mention this. I had the same exact thought when I read about the failure of Abbott's kidney program. The also have a Parkinson's candidate in Phase 3 so all of the sudden the tardive dyskinesia program looks like an interesting fit for Abbott. I've always felt that NBIX should be bought by Abbott. The pipeline isn't as robust as it used to be, but elagolix has such huge potential. Abbott needs to build their story as you said. It's really important for them.

      • 1 Reply to investormdpart2
      • I remember emailing Dr. O'Brien over a year ago and asked him if VMAT2 might be applicable to Parkinson's. My thinking was apparently like yours in that both tardive and Parkinson's are characterized by involuntary movements. His answer was no, but I can't remember why. Perhaps something about different receptors. If Abbott does go after NBIX, let's hope we start the bidding at a higher level than seven or eight bucks. I don't see them offering a 100% premium.


45.67+1.37(+3.09%)Oct 20 4:00 PMEDT